Systemic sclerosis & Raynaud's
Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis
Main finding · High GI severity (Medsger ≥2)Result — go to the resultOdds ratio 4.50 95% CI 1.11–18.18Authors' conclusion
Anti-M3R antibodies are associated with a more severe GI phenotype and distinct extraintestinal and serological features in SSc patients.
Study context
- Population
- SSc patients in a cohort enriched for gastrointestinal (GI) symptoms52 (39.4%) anti-M3R positive
- Participants
- 132 patients
- Exposure
- SSc patients with vs without high-titre anti-M3R antibodies
- High-titre anti-M3Rn = 33
- Outcome
- GI and extraintestinal features associated with high-titre anti-M3R antibodies, incl. high GI severity (Medsger GI Severity Score ≥2)
Methodological detailscohort enriched for GI symptoms, high titre defined a priori as top quartile of anti-M3R titres, multivariable logistic regression
- Cohort enriched for GI symptoms
- High titre defined a priori as top quartile of anti-M3R titres
- Multivariable logistic regression
Main finding
High GI severity (Medsger ≥2)
Odds ratio
4.50
95% CI 1.11–18.18
P = 0.035
By group
High-titre anti-M3Rvs Without high titres
OR 4.50 (95% CI 1.11–18.18); P = 0.035
As reported in the abstract
Observational data: associations, not effects.
Further findings
Diffuse disease
P = 0.023
Anti-RNPC3 antibodies
P = 0.036
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Anti-U1RNP antibodiesMultivariable logistic regression | 20.36 (3.16–131.14) | P = 0.002 | |
| 0.050.21520Odds ratio (log scale) |
| Outcome | High-titre anti-M3R | Without high titres | P value |
|---|---|---|---|
| Anti-U1RNP antibodies | 21.2 | 2.0% | P = 0.001 |
Whole-gut transit studies and UCLA GIT 2.0 scores
- Not different between the groups
Original publication
Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis. Rheumatology (Oxford). Published 12 April 2025. doi:10. 1093/ rheumatology/ keaf197
Composed by AI from the published abstract and checked against it. How Briefs are made →